OncoSec Medical Inc (ONCSQ)

[Titan V]

In other news..
http://www.medscape.com/viewarticle/835553

..."We've had amazing clinical success treating patients battling advanced melanoma with pembrolizumab (Keytruda, Merck & Co). The challenge is that it only works in approximately 30% of patients with melanoma," Dr Tumeh toldMedscape Medical News."...

..."The research into predicting which patients are likely to respond to immunotherapies is very important, Dr Chan said. These drugs have significant toxicities and cost, he pointed out, and being able to identify patients who are not likely to benefit will spare patients both."..

The article mentions the need to identify patients who would respond to Keytruda before spending time and money on treatment. OncoSec on the other hand is working on increasing the response rate itself instead of identifying nonresponders and turning them away from treatment. This is why I'm invested in OncoSec.